Pesigan T P, Banzon T C, Santos A T, Noseñas J, Zabala R G
Bull World Health Organ. 1967;36(2):263-74.
Trials have been carried out, first on a relatively small scale among patients in Manila and later on a larger scale among domiciliary patients in an area of endemic schistosomiasis in Leyte Province, Philippines, with various dosage schedules of pararosaniline pamoate (CI-403-A) to determine that drug's efficacy and optimum dosage against Schistosoma japonicum infection.Given orally in gelatin capsules, the drug was well tolerated even in children, with few side-effects, and was both curative and suppressive when administered in a maximum dosage of 35-40 mg/kg body-weight per day for as many as 52 days spread over a total treatment period of 203 days.The authors recommend its use for mass treatment, especially among schoolchildren, in combination with other established schistosomiasis control measures-health education, environmental sanitation, and snail control.
已开展了多项试验，首先在马尼拉的患者中进行了相对小规模的试验，随后在菲律宾莱特省血吸虫病流行地区的居家患者中进行了更大规模的试验，采用了不同剂量方案的对氨基苯磺酸副蔷薇苯胺（CI - 403 - A），以确定该药物对日本血吸虫感染的疗效和最佳剂量。该药物以明胶胶囊口服给药，即使在儿童中也耐受性良好，副作用很少，当以每天每公斤体重35 - 40毫克的最大剂量给药长达52天，总治疗期为203天时，具有治疗和抑制作用。作者建议将其用于大规模治疗，特别是在学童中，并与其他既定的血吸虫病控制措施——健康教育、环境卫生和灭螺相结合。
